Evotec

Evotec is a highly innovative, deeply scientific life science company that successfully operates a highly unique, dual-business model strictly focused on discovering, developing, and manufacturing highly effective novel therapeutics. Based in Hamburg, Germany, Evotec perfectly combines its extensive, world-class drug discovery platforms (operating under the EVOexecute division) with a highly robust, deeply valuable portfolio of co-owned pipeline programs (operating under the EVOinnovate division).

Evotec distinctly does not function as a traditional, passive fee-for-service CRO; instead, they act as highly active, deeply invested scientific partners, very often engaging in complex risk-sharing, milestone-based alliances with their clients. The company boasts industry-leading, cutting-edge capabilities in high-throughput screening, advanced structure-based drug design, complex multi-omics data analysis, and revolutionary induced pluripotent stem cell (iPSC) technology.

Their advanced iPSC platforms are particularly groundbreaking in the industry, allowing for highly accurate, humanized disease modeling primarily in complex neurology and metabolic diseases, which drastically improves preclinical predictability.

Furthermore, Evotec has fundamentally revolutionized modern biomanufacturing through its highly innovative subsidiary, Just – Evotec Biologics, utilizing proprietary J.POD® technology—small, highly flexible, fully continuous biomanufacturing facilities that drastically reduce the capital cost and footprint of biologic production globally.